View Post

Research KSQ boosts PARP inhibition in animal models of ovarian and breast cancers with USP1 inhibitor

In Clinical Studies News by Barbara Jacoby

By: Arlene Weintraub From: fiercebiotech.com PARP inhibitors like Lynparza from Merck and AstraZeneca have been effective in some patients with ovarian and breast cancers, but many develop resistance to the drugs, and some people don’t respond at all. KSQ Therapeutics hopes to provide hope for those patients with a first-in-class drug that may be able to boost Lynparza’s effectiveness when …

View Post

Optimal Sequencing Remains a Hurdle in Ovarian Cancer Treatment

In Clinical Studies News by Barbara Jacoby

By: Brittany Lovely From: onclive.com The surge of treatment options for patients with ovarian cancer poses a daunting challenge as answers for optimal sequencing continue to elude clinicians. Bevacizumab (Avastin) continues to hold the most utility in this disease setting, but the addition of PARP inhibitors, and immunotherapy raises the question of how to best deliver efficient regimens to patients. …

View Post

Navicixizumab Combo Shows Benefit in Heavily Pretreated Ovarian Cancer

In Clinical Studies News by Barbara Jacoby

By: Jason M. Broderick From: onclive.com The anti-DLL4/VEGF bispecific antibody navicixizumab showed promising clinical activity when used in combination with paclitaxel in heavily pretreated patients with platinum-resistant ovarian cancer, according to findings from a phase Ib study. The data build on positive single-agent phase Ia data previously shared. The phase Ib results showed that the overall response rate per RECIST …

View Post

Test measures immune response to improve ovarian cancer diagnosis

In Clinical Studies News by Barbara Jacoby

Source: RMIT University From: miragenews.com Researchers have developed a simple blood test that measures the body’s own immune response to improve diagnosis of ovarian cancer. Ovarian cancer is one of the most common gynaecologic cancers, with the highest mortality rate. About 300,000 new cases are diagnosed globally each year, with an estimated 60% of women dying within five years after …

View Post

Understanding Prevention For Hereditary Cancer

In In The News by Barbara Jacoby

By: Sue Friedman From: curetoday.com My first encounter with hereditary cancer came in 1996 when I was 33. I was early in my career as a veterinarian, a mother to a one-year-old, and preparing to have another child. Then, I was diagnosed with breast cancer. My diagnosis came out of the blue. I didn’t have a profound family history of …

View Post

UMass Amherst Researcher Aims to Develop New Screening for BRCA-Positive Breastfeeding Women

In Clinical Studies News by Barbara Jacoby

Contact: Kathleen Arcaro 413-577-1823 From: umass.edu Groundbreaking Study is Recruiting Lactating Moms from Across the Country Breastfeeding women with a pathogenic BRCA1 or BRCA2 genetic mutation face a significant risk, even at a young age, of breast and ovarian cancer. Yet no fully effective breast cancer screening method exists for nursing mothers in this high-risk group, some of whom are …

View Post

Payer CMS approves Medicare coverage of next-generation sequencing tests for inherited ovarian, breast cancers

In In The News by Barbara Jacoby

By: Robert King From: fiercehealthcare.com Medicare can now cover breakthrough laboratory diagnostic tests that use Next Generation Sequencing for patients with inherited ovarian or breast cancer. The decision announced Monday by the Centers for Medicare & Medicaid Services is the latest move by the agency to address how to cover costly new cancer diagnostics and treatments. CMS decided to first …

View Post

Premier Health offers new ovarian cancer clinical trial

In Clinical Studies News by Barbara Jacoby

From: dailycall.com Premier Health is the first health system in the United States to offer a new Phase III study for women who have been newly diagnosed with Stage III or IV BRCA negative ovarian cancer. This clinical trial, KEYLYNK-001, examines how the addition of a cancer immunotherapy drug, Keytruda, and an oral prescription medication known as a PARP inhibitor, …

View Post

Transgene and NEC Start Two Clinical Trials with TG4050, an Individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers

In Clinical Studies News by Barbara Jacoby

From: businesswire.com TG4050 moves therapeutic vaccination into the digital age: combines Transgene’s expertise in viral vectors with NEC’s cutting-edge Artificial Intelligence (AI) capabilities Novel immunotherapy is fully tailored to each individual by generating an immune response that targets highly specific patient tumor mutations First patients enrolled in two Phase 1 trials at the Mayo Clinic and Toulouse Oncopole Transgene (Paris:TNG) …

View Post

Isolated perfusion therapy with chemofiltration leads to rapid remissions with maintained and improved quality of life for women with ovarian cancer

In In The News by Barbara Jacoby

Source: Medias-Klinikum Burghausen Ovarian tumours are among the most aggressive cancers in women and rank fifth in all gynaecological cancers. The disease is often only recognised very late and is then hardly controllable. Only about one third of the patients survive the five years after the initial diagnosis. If metastases have already formed in the abdomen, often only a radical …